Diagnostic Center | May 03, 2025
AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease